NASDAQ$SMTI

Sanara MedTech Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Sanara MedTech reported record revenue driven by increased facilities, higher average sales per facility, and expanded product lines.

Sanara MedTech Inc. announced record revenue for the first quarter of 2023, with March being the highest sales month in the company's history. The growth was driven by an increased number of facilities selling their products, higher average sales per facility, and the promotion of expanded product lines. The company also submitted its Precision Healing Multispectral Imager for 510(k) clearance and received 510(k) clearance for BIASURGE™ Advanced Surgical Solution, with commercial launch preparation underway for late 2023.

  • Achieved record revenue in Q1 2023.
  • March marked the highest sales month in the Company’s history.
  • Revenue growth driven by increased facilities, higher average sales per facility, and expanded product lines.
  • Received 510(k) clearance for BIASURGE™ Advanced Surgical Solution and preparing for commercial launch in late 2023.

Headline financials

Total Revenue

$15.5M

Previous: $7.81M+98.7%
EPS (adj)

-$0.14

Previous: -$0.41+65.9%
Capital Expenditures

-$27.7K

Previous: -$44.7K+38.0%
Free Cash Flow

-$1.21M

Previous: -$3.2M+62.3%
Net Income

-$1.18M

Previous: -$3.16M+62.7%
Operating Income

-$1.22M

Previous: -$2.78M+56.2%
Gross Profit

$13.4M

Previous: $7.01M+91.2%
Cash & Equivalents

$7.29M

Previous: $16.1M-54.9%
Total Assets

$60M

Previous: $33.9M+76.7%
Stock-Based Comp

$597K

Previous: $585K+2.1%

Revenue & EPS history

Sanara MedTech · Revenue · Quarterly

$15.5M

Q1 2023+98.7%vs Q1 2022
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Sanara MedTech · $31.6M total across 2 segments · Q2 2023

  • Soft tissue repair
    $15.8M
  • Bone fusion products
    $15.8M

Forward guidance

The company anticipates resolution of the supply issues in the second half of 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.1%

Avg return

Earnings day

-2.5%

Avg return

5 days after

+1.6%

Avg return

30 days after

34%

22 / 65 earnings

Positive

+28.6%

Q4 2014

Best reaction

-25.0%

Q3 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-0.3%-12.1%
Q1 2026+13.0%+17.3%+19.5%
Q3 2025-23.4%-24.9%-7.6%
Q2 2025-4.8%-3.3%+6.4%
Q1 2025-9.0%-11.2%-17.9%
Q4 2024-12.6%-15.4%-10.4%
Q3 2024+6.3%-1.0%+2.5%
Q2 2024+14.9%+16.3%+20.2%
Q1 2024-5.0%-2.9%-0.5%
Q4 2023-1.8%-1.1%-13.1%
Q3 2023+18.8%+15.3%+37.5%
Q2 2023-12.5%-13.6%-22.6%
Q1 2023-5.0%-9.2%-5.9%
Q4 2022-0.1%-4.1%+17.9%
Q3 2022+4.1%+7.2%+3.2%
Q2 2022+1.2%-1.7%+13.4%
Q1 2022+5.0%+2.3%-12.2%
Q4 2021+2.5%+10.7%-10.9%
Q3 2021-1.6%-2.2%-15.8%
Q2 2021-8.3%-12.4%-14.5%
Q1 2021+5.2%+14.9%+28.7%
Q4 2020+14.5%+6.8%-4.5%
Q3 2020-4.5%-4.3%+15.7%
Q2 2020+9.8%+13.7%+37.2%
Q1 2020-20.7%-18.2%+28.8%
Q4 2019-4.3%+7.3%+30.9%
Q3 2019-3.9%-5.7%+5.1%
Q2 2019-11.5%-20.1%-17.2%
Q1 2019+0.0%-16.7%-16.7%
Q4 2018+0.0%-16.7%-16.7%
Q3 2018+0.0%+0.0%+0.0%
Q2 2018-10.0%-10.0%-30.0%
Q1 2018+20.0%+0.0%+20.0%
Q4 2017+20.0%+0.0%+20.0%
Q3 2017+0.0%+0.0%-14.3%
Q2 2017+0.0%+16.7%+16.7%
Q1 2017+0.0%+0.0%-22.2%
Q4 2016+0.0%+0.0%-10.0%
Q3 2016-20.0%-20.0%+0.0%
Q2 2016+20.0%+0.0%+0.0%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015+0.0%
Q2 2015+0.0%
Q1 2015+11.1%
Q4 2014+28.6%
Q3 2014+0.0%
Q2 2014+0.0%
Q1 2014+0.0%
Q4 2013+0.0%
Q3 2013+14.3%
Q2 2013+0.0%
Q1 2013+16.7%
Q4 2012-12.5%
Q3 2012-16.7%
Q2 2012+6.7%
Q1 2012+0.0%
Q4 2011-4.3%
Q3 2011+0.0%
Q2 2011-10.3%
Q1 2011-11.1%
Q4 2010+3.1%
Q3 2010-25.0%
Q2 2010+2.9%
Q1 2010+5.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro